AL-101 is under clinical development by Alector and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-101 overview
AL-101 is under development for the treatment of neurological disorders like early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD and Parkinson’s disease. The drug candidate is recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z, a)] kappa monoclonal antibody. It acts by targeting sortilin1 (SORT1) receptor. It is administered through intravenous and subcutaneous route.
It was under development for the treatment of neurological disorders like frontotemporal dementia.
Alector overview
Alector is a biotechnology company that develops therapies for the immune system to cure neurodegeneration and cancer. The company’s pipeline products include AL001, AL101 and AL002 target Alzheimer’s and frontotemporal dementia diseases. It combines state-of-the-art antibody technology and recent discoveries in neuroimmunology and oncology to fight cancer. Alector also generates and validates antibody drugs that are into disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. Alector is headquartered in South San Francisco, California, the US.
For a complete picture of AL-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
